PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS :C000138383	ACCESSION NO : 0080WB006704	AGE/SEX : 41 Years Male	
	PATIENT ID :ANKIM22018280	DRAWN :	
PROVISIONAL REPORT	CLIENT PATIENT ID:	RECEIVED : 18/02/2023 09:23:28	
	ABHA NO :	REPORTED :18/02/2023 14:22:27	
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units	

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE THYROID PANEL, SERUM

ng/dL
ig/uL
ug/dL
uIU/mL
μ

Page 1 Of 13



View Details View Report

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WB006704	AGE/SEX : 41 Years Male		
	PATIENT ID :ANKIM22018280	DRAWN :		
PROVISIONAL REPORT	CLIENT PATIENT ID:	RECEIVED : 18/02/2023 09:23:28		
	ABHA NO :	REPORTED :18/02/2023 14:22:27		
Test Report Status Final	Results Biologic	al Reference Interval Units		

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECK UP AF	BOVE 40 MALE			
BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB) METHOD : CYANMETHEMOGLOBIN METHOD	13.8	13.0 - 17.0	g/dL	
RED BLOOD CELL (RBC) COUNT	4.93	4.5 - 5.5	mil/µL	
WHITE BLOOD CELL (WBC) COUNT	6.70	4.0 - 10.0	thou/µL	
PLATELET COUNT	282	150 - 410	thou/µL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	42.1	40.0 - 50.0	%	
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	85.4	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	27.9	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.7	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : CALCULATED PARAMETER	16.0 High	11.6 - 14.0	%	
MENTZER INDEX	17.3			
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	8.5	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CELLS I	69 Impedence	40 - 80	%	
LYMPHOCYTES METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CELLS I	21 IMPEDENCE	20 - 40	%	
MONOCYTES METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CELLS I	9 IMPEDENCE	2.0 - 10.0	%	
EOSINOPHILS	1	1.0 - 6.0	%	
BASOPHILS	0	0 - 1	%	
METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CELLS I	MPEDENCE			
ABSOLUTE NEUTROPHIL COUNT	4.62	2.0 - 7.0	thou/µL	
ABSOLUTE LYMPHOCYTE COUNT	1.41	1.0 - 3.0	thou/µL	

Page 2 Of 13



PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF				
CODE/NAME & ADDRESS :C000138383	ACCESSION NO : 00	080WB006704	AGE/SEX	:41 Years	Male
PROVACIONAL DEPODE	PATIENT ID : AN	NKIM22018280	DRAWN	:	
PROVISIONAL REPORT	CLIENT PATIENT ID:		RECEIVED	:18/02/2023	09:23:28
	ABHA NO :		REPORTED	:18/02/2023	14:22:27
Test Report Status <u>Final</u>	Results	Biological	Reference	e Interval L	Inits
ABSOLUTE MONOCYTE COUNT	0.60	0.2 - 1.0		tho	u/µL
			•		
ABSOLUTE EOSINOPHIL COUNT	0.07	0.02 - 0.5	0	tho	u/µL
ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED PARAMETER	0.00 Low	0.02 - 0.1	0	tho	u/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED PARAMETER	3.3				

Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Page 3 Of 13



View Details View Report

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WB006704	AGE/SEX :41 Years Male		
DROVICIONAL REPORT	PATIENT ID : ANKIM22018280	DRAWN :		
PROVISIONAL REPORT	CLIENT PATIENT ID:	RECEIVED : 18/02/2023 09:23:28		
	ABHA NO :	REPORTED :18/02/2023 14:22:27		
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units		

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CH	IECK UP ABOVE 40 MALE		
ERYTHROCYTE SEDIMENTATION RA	TE (ESR),WHOLE		
E.S.R	33 High	0 - 14	mm at 1 hr
METHOD · MODIFIED WESTERGREN			

Interpretation(s) ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.



View Report View Details

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WB006704	AGE/SEX :41 Years Male	
	PATIENT ID : ANKIM22018280	DRAWN :	
PROVISIONAL REPORT	CLIENT PATIENT ID:	RECEIVED : 18/02/2023 09:23:28	
	ABHA NO :	REPORTED :18/02/2023 14:22:27	
[<u> </u>		
Test Report Status <u>Final</u>	Results Biologica	al Reference Interval Units	

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE B METHOD : SLIDE AGGLUTINATION RH TYPE POSITIVE

METHOD : SLIDE AGGLUTINATION

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Page 5 Of 13



View Details View Report

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WB006704	AGE/SEX :41 Years Male		
	PATIENT ID : ANKIM22018280	DRAWN :		
PROVISIONAL REPORT	CLIENT PATIENT ID:	RECEIVED : 18/02/2023 09:23:28		
	ABHA NO :	REPORTED :18/02/2023 14:22:27		
	1	<u> </u>		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

ſ	BIOCHEMISTRY)
L MEDI WHEEL FULL BODY HEALTH CHECK UP			J
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT			
HBA1C	5.3	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	% 6.5
ESTIMATED AVERAGE GLUCOSE(EAG) GLUCOSE FASTING,FLUORIDE PLASMA	105.4	< 116.0	mg/dL
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	85	74 - 106	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR)	82	Non-Diabetes 70 - 140	mg/dL
METHOD : HEXOKINASE			
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	139	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE			
TRIGLYCERIDES	73	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
METHOD : ENZYMATIC ASSAY			
HDL CHOLESTEROL METHOD : DIRECT MEASURE - PEG	45	< 40 Low >/=60 High	mg/dL

Page 6 Of 13



View Details View Report

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WB006704		AGE/SEX :41 Years	s Male
PROVINCIONAL REPORT	PATIENT ID : ANKIM	22018280	DRAWN :	
PROVISIONAL REPORT	CLIENT PATIENT ID:		RECEIVED : 18/02/2	023 09:23:28
	ABHA NO :		REPORTED :18/02/2	2023 14:22:27
Test Report Status <u>Final</u>	Results	Biologica	al Reference Interva	I Units
	70	100.0		
CHOLESTEROL LDL	79	< 100 O 100 - 12		mg/dL
			above optimal	
		130 - 15		
		Borderlir 160 - 18	-	
		160 - 18 High	בי	
		>/= 190		
		Very Hig	h	
METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE	04	D · · · ·		
NON HDL CHOLESTEROL	94	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159		mg/dL
			ne High: 160 - 189	
		High: 19	0 - 219	
		Very hig	h: > or = 220	
	14.6	Desirable		mg/dL
VERY LOW DENSITY LIPOPROTEIN	14.0	10 - 35	e value :	ilig/uL
METHOD : CALCULATED PARAMETER		10 00		
CHOL/HDL RATIO	3.1 Low	3.3-4.4		
			Average Risk	
) Moderate Risk ligh Risk	
METHOD : CALCULATED PARAMETER				
LDL/HDL RATIO	1.8		Desirable/Low Risk	
) Borderline/Modera	te
		Risk >6.0 Hig	ıh Risk	
METHOD : CALCULATED PARAMETER		2 010 1119		
Interpretation(s)				
LIVER FUNCTION PROFILE, SERUM				
BILIRUBIN, TOTAL	0.57	UPTO 1.2	2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE)				
BILIRUBIN, DIRECT	0.19	0.00 - 0.	.30	mg/dL
METHOD : DIAZOTIZATION				
BILIRUBIN, INDIRECT	0.38	0.00 - 0.	.60	mg/dL
METHOD : CALCULATED PARAMETER	7.0		,	a (d)
TOTAL PROTEIN	7.0	6.6 - 8.7	7	g/dL

Page 7 Of 13



PATIENT NAME : ANKIT GOEL		REF. DOCTOR : S	
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080	JWB006704	AGE/SEX :41 Years Male
PROVISIONAL REPORT	PATIENT ID : ANKIM22018280		DRAWN :
PROVISIONAL REPORT	CLIENT PATIENT ID:		RECEIVED : 18/02/2023 09:23:28
	ABHA NO :		REPORTED :18/02/2023 14:22:27
Test Report Status <u>Final</u>	Results	Biological	Reference Interval Units
METHOD : BIURET			
ALBUMIN	4.2	3.97 - 4.9	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN	2.8	2.0 - 4.0	g/dL
		Neonates Pre Mature	
		0.29 - 1.0	-
METHOD : CALCULATED PARAMETER		0122 2	
ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.0	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	16	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : UV WITHOUT PYRIDOXAL-5 PHOSPHATE	13	0 - 41	U/L
ALKALINE PHOSPHATASE METHOD : PNPP - AMP BUFFER	71	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	14	8 - 61	U/L
LACTATE DEHYDROGENASE METHOD : LACTATE -PYRUVATE	149	135 - 225	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD : UREASE - UV	16	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD : ALKALINE PICRATE-KINETIC	1.16	0.70 - 1.2	0 mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD : CALCULATED PARAMETER	13.79	5.00 - 15.	00
URIC ACID, SERUM			
URIC ACID METHOD : URICASE, COLORIMETRIC	6.4	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN, SEROM	7.0	6.6 - 8.7	g/dL
METHOD : BIURET	7.0	0.0 - 0.7	9, uL

Page 8 Of 13



PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 008	OWB006704 AGE/SEX	< :41 Years Male
	PATIENT ID : ANKIM22018280 DRAWN		:
PROVISIONAL REPORT	CLIENT PATIENT ID:	RECEIVE	ED :18/02/2023 09:23:28
	ABHA NO :	REPORTE	ED :18/02/2023 14:22:27
Test Report Status <u>Final</u>	Results	Biological Referer	nce Interval Units
ALBUMIN METHOD : BROMOCRESOL GREEN	4.2	3.97 - 4.94	g/dL
GLOBULIN			
GLOBULIN	2.8	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD : ISE INDIRECT	139	136 - 145	mmol/L
POTASSIUM, SERUM METHOD : ISE INDIRECT	4.79	3.5 - 5.1	mmol/L
CHLORIDE, SERUM METHOD : ISE INDIRECT	104	98 - 107	mmol/L
Interpretation(s)			

Interpretation(s) GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbAtc to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as eAG (mg/dl) = 28.7 * HbAtc - 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine. Increased in

Page 9 Of 13



View Details View Report

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WB006704	AGE/SEX :41 Years Male	
DROUMOTONIAL DEPORT	PATIENT ID : ANKIM22018280	DRAWN :	
PROVISIONAL REPORT	CLIENT PATIENT ID:	RECEIVED : 18/02/2023 09:23:28	
	ABHA NO :	REPORTED :18/02/2023 14:22:27	
Test Report Status Final	Results Biological	Reference Interval Units	

Diabetes mellitus, Cushing' s syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g., galactosemia), Drugs- insulin,

ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE Billrubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is very bilirubin elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin elev there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis.obstruction of bile ducts.cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget'''s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson'''s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom'''s

globulin.Higher-than-normal levels may be due to: Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstrom^{IIII}'s disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)

- Muscle problems, such as breakdown of muscle fibers
 Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

URIC ACID, ŚERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Page 10 Of 13



View Report View Details

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS :C000138383	ACCESSION NO : 0080WB006704	AGE/SEX :41 Years Male	
PROVISIONAL REPORT	PATIENT ID :ANKIM22018280	DRAWN :	
	CLIENT PATIENT ID:	RECEIVED : 18/02/2023 09:23:28	
	ABHA NO :	REPORTED :18/02/2023 14:22:27	
Test Report Status Final	Results Biologic	cal Reference Interval Units	

Biological Reference Interval Units

	CLINICAL PATH - URINALYSIS	5	
MEDI WHEEL FULL BODY HEALTH CHEC	CK UP ABOVE 40 MALE		
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
APPEARANCE	CLEAR		
CHEMICAL EXAMINATION, URINE			
РН	6.0	4.7 - 7.5	
METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUB	LE INDICATOR METHOD		
SPECIFIC GRAVITY	1.020	1.003 - 1.035	
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PKA C	HANGE OF PRETREATED POLY ELECTROLYTES)		
PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PROTE	EIN-ERROR-OF-INDICATORS PRINCIPLE)		
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY(GLUCC	DSE OXIDAE/PEROXIDASE METHOD)		
KETONES	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY (SODIU			
BLOOD	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PERO)			
BILIRUBIN	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY (DIAZO			
UROBILINOGEN METHOD : REFLECTANCE SPECTROPHOTOMETRY - EHRL		NORMAL	
NITRITE		NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONV	NOT DETECTED	NUI DEIECIED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
			/HPF
RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	/1166
PUS CELL (WBC'S)	0-1	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION	0-1	0-5	/1111
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION	01	0.5	,
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		

Page 11 Of 13



View Details View Report

Test Report Status

<u>Final</u>

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080W	B006704	AGE/SEX :41 Years Male
PROVISIONAL REPORT	PATIENT ID : ANKIM2	2018280	DRAWN :
	CLIENT PATIENT ID:		RECEIVED : 18/02/2023 09:23:28
	ABHA NO :		REPORTED :18/02/2023 14:22:27
Test Report Status <u>Final</u>	Results	Biologica	I Reference Interval Units
METHOD : MICROSCOPIC EXAMINATION			
BACTERIA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DET	ECTED
YEAST	NOT DETECTED	NOT DET	ECTED

Interpretation(s)

Page 12 Of 13



View Details View Report

PATIENT NAME : ANKIT GOEL	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WB006704	AGE/SEX :41 Years Male	
DROUMONONAL DERODE	PATIENT ID : ANKIM22018280	DRAWN :	
PROVISIONAL REPORT	CLIENT PATIENT ID:	RECEIVED :18/02/2023 09:23:28	
	ABHA NO :	REPORTED :18/02/2023 14:22:27	
(i	i	

Test Report Status Final

Results

Biological Reference Interval Units

.....

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR

SAMPLE NOT RECEIVED

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Page 13 Of 13



View Details View Report